Norstella launches new fully integrated data asset to support drug development

NorstellaLinQ is the biopharma industry's first fully integrated data asset, combining 74 billion data points, including real-world data (RWD), to enhance drug development and decision-making.

Norstella has introduced NorstellaLinQ, the biopharma industry's first fully integrated data asset, designed to enhance drug development and commercialization. This comprehensive platform integrates over 74 billion data points, combining RWD with Norstella's proprietary intelligence. The dataset includes open and closed claims, lab results, structured and unstructured electronic medical records (EMRs), as well as critical forecasting, clinical, regulatory, and commercial insights.

NorstellaLinQ aims to support more efficient decision-making across all stages of the drug development lifecycle, addressing the challenges and high costs associated with bringing new drugs to market. Norstella, with its extensive experience supporting global pharmaceutical and life sciences companies, has combined the expertise of its brands – Citeline, Evaluate, MMIT, Panalgo, and The Dedham Group – to create this comprehensive data solution. By providing access to the most connected dataset in the industry, NorstellaLinQ enables organizations to make more informed decisions and optimize strategies throughout the entire drug development process.

The system integrates data from 500,000 investigators, tens of thousands of clinical trials, hundreds of product launches, and tens of thousands of forecasts. This vast dataset enables companies to make informed decisions on portfolio planning, investigator selection, patient recruitment, and product launches. NorstellaLinQ also leverages AI, machine learning, and large language models (LLMs) to deliver predictive analytics and customized visualizations. With 1.5 million tagged records mapped to 55 custom and standard ontologies, the platform provides detailed data coverage across the entire drug development process, improving the accuracy and efficiency of identifying patient populations that may benefit from therapies.

---

“NorstellaLinQ isn’t just about bringing together data,” said Mike Gallup, CEO of Norstella. “It’s about creating the only solution in the market that links real-world patient data with the proprietary intelligence of Norstella’s most trusted brands that have powered the pharmaceutical industry for decades. NorstellaLinQ provides our clients with a transformative capability to analyze, predict and act on insights that no other solution can deliver, truly smoothing the path from pipeline to patient.”

---

A recent Norstella survey of over 100 pharmaceutical executives revealed that nearly half of the respondents identified data integration and cleanliness as key challenges in adopting new technologies. NorstellaLinQ addresses these issues by providing a streamlined, integrated data platform that supports the development of more efficient drug development strategies and informed decision-making across the product lifecycle.

The platform supports multiple teams across the biopharma ecosystem, including clinical operations, clinical trial recruitment, brand management, and market access. Clinical operations teams can optimize protocol design and investigator selection, while clinical trial teams leverage predictive analytics to improve patient recruitment efforts. Market access teams benefit from the ability to track restrictive insurance practices, enabling them to advocate for faster access to therapies.